Low Levels Of Vitamin B9 Linked To Dementia Risk
March 15, 2022
Using The Scientific Principles Of Cellular Medicine To Improve The Health, Behavior, And Future Economic Livelihoods Of Prisoners In Uganda
March 18, 2022

Moderna’s Profits Show Why Big Pharma Can’t Meet Our Health Needs

News

“Last month, COVID-19 vaccine maker Moderna announced its financial results for 2021. They confirmed that Moderna’s vaccine is one of the most lucrative medicines of all time, bringing in nearly $18bn in revenue for the company in a single year. ” [Source: aljazeera.com]

Comment

Moderna is hardly alone in making skyrocketing sums of money from COVID-19. Pfizer’s vaccine has brought in $37 billion, for example, making it one of the most profitable products in history. It should thus come as no surprise that both Pfizer and Moderna are now claiming people need a fourth dose of their COVID-19 vaccines. Given the vast profits they make, each of these companies has a vested interest in promoting the idea that repeated so-called ‘booster’ doses are needed on a regular basis.

What is equally significant here is that major drug companies have been resisting demands for them to waive the patents on their COVID-19 vaccines and share the technology with smaller manufacturers in poorer countries. This only further confirms what we have always said about the pharma industry, namely, that it is driven not by human health but by the profits it makes for its shareholders.

The enormous profits made by the likes of Pfizer and Moderna are a direct result of the fact that their drugs and vaccines can be patented, thus allowing them to create and control multibillion dollar markets. Maintaining the existence of diseases and expanding their incidence globally is a precondition for these profits to continue. Seen in this light, the pharma industry essentially has no interest in the COVID-19 pandemic being declared over anytime soon.

To learn more about the true nature of the pharma industry, see the ‘Laws of the Pharmaceutical Industry’ feature on our website.